Browse > Article
http://dx.doi.org/10.17946/JRST.2020.43.5.389

A Study on the Radioactive Products of Components in Proton Accelerator on Short Term Usage Using Computed Simulation  

Bae, Sang-Il (Dept. of Radiation Oncology, Dongnam Institute of Radiological & Medical Science)
Kim, Jung-Hoon (Dept. of Radiological Science, College of Health Sciences, Catholic University)
Publication Information
Journal of radiological science and technology / v.43, no.5, 2020 , pp. 389-395 More about this Journal
Abstract
The evaluation of radioactivated components of heavy-ion accelerator facilities affects the safety of radiation management and the exposure dose for workers. and this is an important issue when predicting the disposal cost of waste during maintenance and dismantling of accelerator facilities. In this study, the FLUKA code was used to simulate the proton treatment device nozzle and classify the radio-nuclides and total radioactivity generated by each component over a short period of time. The source term was evaluated using NIST reference beam data, and the neutron flux generated for each component was calculated using the evaluated beam data. Radioactive isotopes caused by generated neutrons were compared and evaluated using nuclide information from the International Radiation Protection Association and the Korea Radioisotope association. Most of the nuclides produced form of beta rays and electron capture, and short-lived nuclides dominated. However, In the case of 54Mn, which is a radioactive product of iron, the effect of gamma rays should be considered. In the case of tritium generated from a material with a low atomic number, it is considered that handling care should be taken due to its long half-life.
Keywords
MCNP; Proton Accelerator; Neutron; Activation product; Bragg peak;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 van de Schoot AJ, de Boer P, Crama KF, Visser J, Stalpers LJ, Rasch CR, et al. Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer. Acta Oncologica. 2016;55(7):892-9.   DOI
2 Choi SG. Literature review of clinical usefulness of heavy ion particle as an new advanced cancer therapy. Journal of Radiological Science and Technology. 2019;42(6):413-22.   DOI
3 Hwang SY, Kim YJ, Lee SW. Evaluation of residual radioactivity and dose rate of a target assembly in an IBA cyclotron. Journal of Radiological Science and Technology. 2016;39(4):643-9.   DOI
4 Fassbender M, Shubin YN, Lunev V, Qaim S. Experimental studies and nuclear model calculations on the formation of radioactive products in interactions of medium energy protons with copper, zinc and brass: Estimation of collimator activation in proton therapy facilities. Applied Radiation and Isotopes. 1997;48(9):1221-30.   DOI
5 Baumer C, Backer CM, Gerhardt M, Grusell E, Koska B, Kroninger K, et al. Measurement of absolute activation cross sections from carbon and aluminum for proton therapy. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 2019;440:75-81.   DOI
6 Bennett G, Goldberg A, Levine G, Guthy J, Balsamo J, Archambeau J. Beam localization via 15O activation in proton-radiation therapy. Nuclear Instruments and Methods. 1975;125(3):333-8.   DOI
7 Yan X, Titt U, Koehler A, Newhauser W. Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2002;476(1-2):429-34.
8 Zheng Y, Newhauser W, Fontenot J, Taddei P, Mohan R. Monte Carlo study of neutron dose equivalent during passive scattering proton therapy. Physics in Medicine & Biology. 2007;52(15):4481.   DOI
9 Agosteo S, Birattari C, Caravaggio M, Silari M, Tosi G. Secondary neutron and photon dose in proton therapy. Radiotherapy and Oncology. 1998;48(3):293-305.   DOI
10 Newhauser W, Titt U, Dexheimer D, Yan X, Nill S. Neutron shielding verification measurements and simulations for a 235-MeV proton therapy center. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2002;476(1-2):80-4.
11 Battistoni G, Boehlen T, Cerutti F, Chin PW, Esposito LS, Fasso A, et al. Overview of the FLUKA code. Annals of Nuclear Energy. 2015;82:10-8.   DOI
12 Tuli JK. Evaluated nuclear structure data file. Brookhaven National Laboratory Nuclear Data Center, Brookhaven, NY; 1987.
13 Aarnio P, Ranft J, Stevenson G, Moehring H, Fasso A, Zazula J, et al. FLUKA: hadronic benchmarks and applications. P00012231; 1993.
14 Guan F. Design and simulation of a passive-scattering nozzle in proton beam radiotherapy. Texas A & M University; 2010.
15 Firestone RB, Shirley VS, CD SFC, Baglin CM. Table of Isotopes (A= 263-272). 1996.
16 Data TID. Technical Report No. 261. Vienna: IaeA. 1986.
17 Han SE, Cho G, Lee SB. An assessment of the secondary neutron dose in the passive scattering proton beam facility of the national cancer center. Nuclear Engineering and Technology. 2017;49(4):801-9.   DOI
18 Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Proton therapy of cancer: Potential clinical advantages and cost-effectiveness. Acta oncologica. 2005;44(8):850-61.   DOI
19 d'Errico F. NCRP Report no. 144-Radiation protection for particle accelerator facilities National Council on Radiation Protection and Measurements Issued 31 December 2003; revised 7 January 2005: NCRP, Bethesda, MD, USA ISBN: 0-929600-77-0, 499 pp, 100(Hardcover), 80 (electronic file downloadable from http://ncrppublications.org). Oxford University Press; 2005.
20 Ipe N, Fehrenbacher G, Gudowska I, Paganetti H, Schippers J, Roesler S. PTCOG publications sub-committee task group on shielding design and radiation safety of charged particle therapy facilities. PTCOG Report. 2010;1.
21 Harrabi S, Bougatf N, Mohr A, Haberer T, Herfarth K, Combs S, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlentherapie und Onkologie. 2016;192(11): 759-69.   DOI